Magacil200 ml

Established Uses

Magacil is indicated for the symptomatic relief of hyperacidity associated with the following conditions:

• Heartburn and acid indigestion
• Gastritis and gastric hyperacidity
• Peptic ulcer disease (duodenal and gastric ulcer) - for relief of associated pain and discomfort
• Gastroesophageal reflux disease (GERD) - for symptomatic relief of reflux-related burning and discomfort
• Hiatal hernia-associated acid symptoms

Adjunct Use

Magacil is commonly used as an adjunct, short-term symptom reliever alongside definitive acid-suppressive therapy (e.g., proton pump inhibitors or H2-receptor antagonists) rather than as sole long-term therapy for peptic ulcer disease or erosive GERD.

Note: Magacil provides rapid, short-acting relief of acid-related symptoms but does not replace physician-directed treatment for underlying disease.

Each dose of Magaldrate contains magaldrate, a chemical complex of hydrated aluminum and magnesium hydroxide, as the active ingredient. It is commonly available as:

• Oral suspension: 400 mg/5 mL (sometimes combined with simethicone in certain formulations)
• Chewable tablets: 400-480 mg per tablet

Formulation and strength may vary by manufacturer; refer to the product label for the exact composition of the specific brand of Magaldrate dispensed.

Magacil is an antacid consisting of a chemical complex of aluminum and magnesium hydroxide. Unlike simple physical mixtures of aluminum and magnesium hydroxide, Magacil is a single hydrated crystalline complex that reacts with stomach acid in a controlled, sequential manner, providing rapid onset of acid-neutralizing action with a reduced tendency for acid rebound compared with some other antacids.

Magacil is available in oral suspension and chewable tablet forms and is widely used for short-term relief of acid-related digestive discomfort.

Magacil belongs to the therapeutic class of Antacid preparations (aluminum-magnesium hydroxide complex antacids).

Mechanism of Action

Magaldrate is a hydrated complex of aluminum and magnesium hydroxide. On contact with gastric hydrochloric acid, the complex dissociates in a sequential, controlled fashion into aluminum hydroxide and magnesium hydroxide, which then neutralize gastric acid, raising intragastric pH. This staged reaction is thought to reduce the acid-rebound phenomenon associated with some faster-acting antacids.

Pharmacodynamics

By raising gastric pH, Magaldrate reduces pepsin activity (pepsin is largely inactive above pH ~4) and provides symptomatic relief of acid-related discomfort. It has minimal systemic absorption when used at recommended doses in patients with normal renal function.

Pharmacokinetics

Magaldrate acts primarily locally within the gastrointestinal tract. Small amounts of aluminum and magnesium may be absorbed systemically; absorbed aluminum and magnesium are excreted primarily by the kidneys, which is the basis for caution in renal impairment (see Precautions and Warnings).

Magacil is administered orally. Shake the suspension thoroughly before measuring a dose, or chew tablets completely before swallowing. It may be taken with or without a small amount of water, generally 1 hour after meals and at bedtime for optimal acid-neutralizing effect.

Reduced Absorption of Other Oral Medications

Magacil can raise gastric pH and chelate certain drugs, thereby significantly reducing the absorption and effectiveness of several oral medications, including:

• Tetracycline antibiotics (e.g., doxycycline) - chelation reduces antibiotic absorption
• Fluoroquinolone antibiotics (e.g., ciprofloxacin, norfloxacin) - chelation reduces antibiotic absorption
• Oral iron supplements - reduced iron absorption
• Digoxin - reduced absorption/effectiveness
• Ketoconazole/itraconazole - reduced absorption due to increased gastric pH
• Thyroid hormone replacement (e.g., levothyroxine)

Management: Separate administration of Magacil from these medications by at least 2 hours (before or after) to minimize interaction.

Common

• Constipation (related to the aluminum component)
• Diarrhea or loose stools (related to the magnesium component)
• Mild stomach cramping

Less Common / With Prolonged High-Dose Use

• Hypophosphatemia (aluminum binds dietary phosphate)
• Hypermagnesemia, particularly in patients with renal impairment (see Precautions and Warnings)

Most side effects of Magacil are mild and resolve with dose adjustment or discontinuation. Seek medical advice if side effects are severe or persistent.

Pregnancy

Magacil has not been formally assigned an FDA pregnancy category. As with most antacids, it is generally used cautiously during pregnancy and should be used only if clearly needed, with potential benefit justifying potential risk. Consult a physician before using Magacil during pregnancy, particularly for use beyond short-term, occasional relief.

Lactation

It is not well established whether components of Magacil pass into breast milk in clinically significant amounts. Use during breastfeeding should be under medical guidance, weighing benefit against any potential risk to the infant.

Renal Impairment

Use Magacil with caution in patients with renal impairment. Reduced renal clearance can lead to accumulation of aluminum and magnesium, which may cause aluminum-related toxicity (e.g., encephalopathy or osteomalacia with prolonged use) or hypermagnesemia (e.g., muscle weakness, hypotension, cardiac arrhythmia, respiratory depression). Chronic, high-dose use of Magacil in patients with renal impairment should be avoided unless directed by a physician.

Masking of Serious Underlying Conditions

Symptomatic relief with Magacil may mask symptoms of more serious gastrointestinal conditions, such as gastric or duodenal ulcer complications, gastrointestinal bleeding, or appendicitis. Seek prompt medical evaluation if abdominal pain persists, worsens, or is accompanied by black/tarry stools, vomiting blood, or severe pain, and do not rely on Magacil alone for more than 2 weeks of self-treatment.

Phosphate Depletion

Chronic use of Magacil, especially with a low-phosphate diet, may lead to phosphate depletion; monitor patients on prolonged therapy, particularly those with poor nutritional intake or alcoholism.

Drug Interactions

Magacil can reduce the absorption of several other oral medications; see Interactions for details and spacing recommendations.

Overdose or excessive chronic use of Magacil may cause diarrhea, electrolyte disturbances, hypermagnesemia (especially in renal impairment), or aluminum accumulation with long-term high-dose use. Symptoms of hypermagnesemia can include muscle weakness, low blood pressure, irregular heartbeat, confusion, and, in severe cases, respiratory depression.

If overdose of Magacil is suspected, seek immediate medical attention or contact a poison control center. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not freeze the oral suspension.

Renal Impairment

Use Magacil with caution; avoid regular/high-dose use due to risk of aluminum and magnesium accumulation (see Precautions and Warnings).

Hepatic Impairment

No specific dose adjustment is well established for hepatic impairment; Magacil acts primarily locally in the GI tract with limited systemic metabolism.

Elderly

Magacil can generally be used in elderly patients but with attention to renal function, which commonly declines with age, and to overall electrolyte status.

Pregnancy and Lactation

See Pregnancy and Lactation section for guidance.

Pediatric Patients

See Pediatric Uses section for guidance.

For self-treatment of occasional heartburn or acid indigestion, Magacil should generally not be used for more than 2 weeks without consulting a physician. For peptic ulcer disease or other physician-diagnosed conditions, the duration of use of Magacil as an adjunct should follow the treating physician's recommendation, alongside definitive acid-suppressive therapy.

Magaldrate is classified under: Antacids; Aluminum-Magnesium Hydroxide Complex.

Magaldrate neutralizes gastric hydrochloric acid through the sequential, controlled dissociation of its aluminum-magnesium hydroxide complex, raising gastric pH and reducing pepsin activity. See Pharmacology for full mechanistic detail.

Safety and efficacy of Magacil have not been well established in children through rigorous controlled pediatric trials. When used in children, Magacil should be given only under the direction and supervision of a physician, with dosing individualized based on age and weight. Magacil is generally not recommended for infants or young children without specific medical guidance.